Modelling of early viral kinetics and pegylated interferon-alpha 2b pharmacokinetics in patients with HBeAg-positive chronic hepatitis B

ter Borg M. J., Hansen B. E., Herrmann E., Zeuzem S., Cakaloglu Y., Karayalcin S., ...Daha Fazla

ANTIVIRAL THERAPY, cilt.12, sa.8, ss.1285-1294, 2007 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 8
  • Basım Tarihi: 2007
  • Dergi Adı: ANTIVIRAL THERAPY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1285-1294
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background: Pegylated interferon alpha 2b (PEG-IFN-alpha 2b) is effective for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, although its mechanism of action remains unclear. HBeAg loss is achieved in 36% of patients after one year of PEG-IFN-a2b treatment and combination therapy with lamivudine is not superior to PEG-IFN-alpha 2b monotherapy.